We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Millipore Acquires Remaining Ownership of Joint Venture in India

By LabMedica International staff writers
Posted on 01 Dec 2009
Millipore Corp. (Billerica, MA, USA) has acquired the remaining 60% ownership of its joint venture in India, Millipore India Pvt., Ltd. The transaction will accelerate strategic growth initiatives in India's thriving life science market.

Based in Bangalore, Millipore India is primarily a sales, service, and manufacturing organization that has additional offices in Ahmedabad, Hyderabad, Kolkata, Mumbai, and Delhi. The joint venture's revenues are split evenly between Millipore's Bioprocess and Bioscience divisions.

The new subsidiary will enable Millipore to invest in initiatives that will drive growth and expand its leadership in India's thriving life-science market. India represents a critical part of the company's strategy to increase its growth by expanding its presence in BRICS (Brazil, Russia, India, China, and Singapore) countries.

There are more than 80 plants in India approved by the United States Food and Drug Administration (FDA; Silver Spring, MD, USA) to manufacture drugs, and the country accounts for almost 25% of the global generic drug market. In addition, the Indian government has invested US$1.7 billion to expand the country's life science and biotechnology industries and several Indian companies have emerged as global competitors in the biopharmaceutical industry.

"India has experienced unprecedented levels of investment and expansion in the country's biotechnology, pharmaceutical, and life science research industries,” said Martin Madaus, chairman & CEO of Millipore. "By establishing direct operations in the country, we will be able to more effectively execute our strategy and leverage our unique capabilities to accelerate growth and support our growing customer base in this dynamic market.”

Related Links:

Millipore
United States Food and Drug Administration




Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Pipette Controller
Sapphire MaxiPette

Latest Industry News

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions
01 Dec 2009  |   Industry

Grifols and Tecan’s IBL Collaborate on Advanced Biomarker Panels
01 Dec 2009  |   Industry

New Collaboration to Advance Microbial Identification for Infectious Disease Diagnostics
01 Dec 2009  |   Industry